CN1298332C - 用于治疗恶性肿瘤的包含亚砷酸盐的药物组合物 - Google Patents

用于治疗恶性肿瘤的包含亚砷酸盐的药物组合物 Download PDF

Info

Publication number
CN1298332C
CN1298332C CNB028287215A CN02828721A CN1298332C CN 1298332 C CN1298332 C CN 1298332C CN B028287215 A CNB028287215 A CN B028287215A CN 02828721 A CN02828721 A CN 02828721A CN 1298332 C CN1298332 C CN 1298332C
Authority
CN
China
Prior art keywords
tumors
pharmaceutical composition
arsenite
malignant tumors
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028287215A
Other languages
English (en)
Chinese (zh)
Other versions
CN1625407A (zh
Inventor
S·B·李
Y·J·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Komi Pharmaceutical International Co ltd
SBLi
YJYang
Original Assignee
YJ Yang
KOREA MICROBIOLOGICAL LAB Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29244880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1298332(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by YJ Yang, KOREA MICROBIOLOGICAL LAB Ltd filed Critical YJ Yang
Publication of CN1625407A publication Critical patent/CN1625407A/zh
Application granted granted Critical
Publication of CN1298332C publication Critical patent/CN1298332C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB028287215A 2002-04-10 2002-04-10 用于治疗恶性肿瘤的包含亚砷酸盐的药物组合物 Expired - Lifetime CN1298332C (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2002/000231 WO2003086424A1 (en) 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Publications (2)

Publication Number Publication Date
CN1625407A CN1625407A (zh) 2005-06-08
CN1298332C true CN1298332C (zh) 2007-02-07

Family

ID=29244880

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028287215A Expired - Lifetime CN1298332C (zh) 2002-04-10 2002-04-10 用于治疗恶性肿瘤的包含亚砷酸盐的药物组合物

Country Status (25)

Country Link
US (1) US20050106262A1 (enExample)
EP (2) EP1496918B1 (enExample)
JP (1) JP2005525397A (enExample)
CN (1) CN1298332C (enExample)
AP (1) AP2004003167A0 (enExample)
AU (2) AU2002253713B2 (enExample)
BG (1) BG66356B1 (enExample)
BR (1) BR0215689A (enExample)
CA (1) CA2481602C (enExample)
CY (1) CY1114422T1 (enExample)
DK (2) DK2042182T3 (enExample)
EC (1) ECSP045408A (enExample)
ES (2) ES2944907T3 (enExample)
FI (1) FI1496918T3 (enExample)
HU (1) HU230851B1 (enExample)
IL (2) IL164470A0 (enExample)
LT (1) LT1496918T (enExample)
MX (1) MXPA04009898A (enExample)
NO (1) NO335317B1 (enExample)
NZ (1) NZ536452A (enExample)
PT (2) PT1496918T (enExample)
RO (1) RO123269B1 (enExample)
TN (1) TNSN04198A1 (enExample)
UA (1) UA80426C2 (enExample)
WO (1) WO2003086424A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024488A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20100249210A1 (en) * 2008-09-30 2010-09-30 Michael Bastiani Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
PL2475362T3 (pl) * 2009-09-10 2019-09-30 Kominox, Inc. Terapia celowana w nowotworowe komórki macierzyste i raka lekoopornego
RU2012108439A (ru) * 2009-09-18 2013-10-27 Коминокс, Инк. Способы лечения опухолей головного мозга
CN101695501B (zh) * 2009-10-10 2013-08-14 广汉恒宇新材料有限公司 一种纳米尺寸亚砷酸的壳聚糖包载体及其制造方法
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804928A1 (en) * 1994-02-18 1997-11-05 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
WO1999018798A1 (en) * 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN1243706A (zh) * 1998-08-02 2000-02-09 哈尔滨医科大学第一临床医学院 治疗消化系统肿瘤注射液及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804928A1 (en) * 1994-02-18 1997-11-05 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
WO1999018798A1 (en) * 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN1243706A (zh) * 1998-08-02 2000-02-09 哈尔滨医科大学第一临床医学院 治疗消化系统肿瘤注射液及其应用

Also Published As

Publication number Publication date
PT1496918T (pt) 2023-05-25
BG66356B1 (bg) 2013-09-30
CY1114422T1 (el) 2016-08-31
DK2042182T3 (da) 2013-08-26
DK1496918T3 (da) 2023-05-15
AU2008255139B2 (en) 2013-10-03
CN1625407A (zh) 2005-06-08
HUP0500199A2 (en) 2007-02-28
PT2042182E (pt) 2013-08-28
ES2944907T3 (es) 2023-06-27
EP1496918A1 (en) 2005-01-19
AP2004003167A0 (en) 2004-12-31
AU2002253713B2 (en) 2008-09-18
ECSP045408A (es) 2006-03-01
BR0215689A (pt) 2005-02-01
EP1496918B1 (en) 2023-02-08
NZ536452A (en) 2007-06-29
JP2005525397A (ja) 2005-08-25
IL164470A (en) 2010-12-30
BG108932A (en) 2005-11-30
TNSN04198A1 (en) 2007-03-12
WO2003086424A1 (en) 2003-10-23
RO123269B1 (ro) 2011-05-30
UA80426C2 (en) 2007-09-25
CA2481602C (en) 2011-06-21
ES2425418T3 (es) 2013-10-15
US20050106262A1 (en) 2005-05-19
AU2002253713A1 (en) 2003-10-27
EP2042182A1 (en) 2009-04-01
CA2481602A1 (en) 2003-10-23
LT1496918T (lt) 2023-05-25
NO20044573L (no) 2004-10-22
NO335317B1 (no) 2014-11-10
MXPA04009898A (es) 2005-06-20
FI1496918T3 (fi) 2023-05-11
IL164470A0 (en) 2005-12-18
AU2008255139A1 (en) 2009-01-08
HUP0500199A3 (en) 2008-03-28
EP2042182B1 (en) 2013-05-22
HU230851B1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
AU2008255139A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
Akaboshi et al. The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration
Mitsui et al. Antitumor activity of polyoxomolybdate,[NH3Pri] 6 [Mo7O24]· 3H2O, against, human gastric cancer model
Köpf-Maier et al. Antitumor activity of some organomettalic bismuth (III) thiolates
Joughi et al. Investigation on the antibacterial properties and rapid infected wound healing activity of silver/laterite/chitosan nanocomposites
EP3291804A1 (en) Targeting intracellular copper ions for inhibiting angiogenesis using nanoparticles of ternary inorganic metal sulfide m1m2s4 (m1, independently, is mg, ca, mn, fe, or zn; m2=mo or w) compounds to treat metastatic cancer
US7816403B2 (en) Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
Bharathi et al. Green synthesized chitosan-coated iron oxide nanocomposite using Cissus quadrangularis plant extract for antibacterial, antioxidant and anticancer applications
AU2008258216A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
Maier et al. The cytotoxic interaction of inorganic trace elements with EDTA and cisplatin in sensitive and resistant human ovarian cancer cells
ZA200408114B (en) Pharmaceutical compositions comprising arsenite for the treatment of malignancy
Hassan et al. Anti-hepatic cancer, antioxidant and anti-inflammatory effects of palladium (II) nano-complex
WO2018124933A1 (ru) Композиция для приготовления противоопухолевого средства и способ приготовления противоопухолевого средства на ее основе
OA12802A (en) Pharmaceutical composition comprising arsenite forthe treatment of malignancy.
JP4571817B2 (ja) 抗菌剤
Al Shammari et al. SYNTHESIS, CHARACTERIZATION AND STUDY THE ANTIBACTERIAL ACTIVITY OF FE 3 O 4 NANOPARTICLES ON E. COLI AND CYTOTOXICITY ON HUVECS.
CN114681471B (zh) 一种硼替佐米和榄香烯分子配伍药物组合及其应用
Rodriguez et al. Zinc, copper, and metallothionein metabolism after jejunoileal bypass surgery or small bowel resection in rats
Buraczewska et al. Differential anti-proliferative properties of novel hydroxydicarboxylatoplatinum (II) complexes with high or low reactivity with thiols
Andronache et al. USE OF MICROMOLECULAR COPPER COMPLEXES OF THIOSEMICARBAZIDES AS AN EN20D2O0GENOUS CATALASE INDUCER/ACTIVATOR
WO2024037498A1 (zh) 一种治疗卵巢癌的联合用药物
Drewinko et al. Comparative cytotoxicity between cisplatin and second generation platinum analogs
CN117838637A (zh) 一种药物辅助的铜纳米颗粒制备方法及其抗肿瘤应用
Zarić Ana Popović, Milos Nikolić, Marina Mijajlović, Zoran Ratković, Verica Jevtić, Srećko R. Trifunović, Gordana Radić
EP2068894A1 (en) Use of cis-rhenium (iii) diadamantate compounds for potentiating the antitumoral activity of platinium complexes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: KOMI MEDICINE INTERNATIONAL CO., LTD.; LEE SANG B.

Free format text: FORMER NAME OR ADDRESS: KOREA MICROBIAL EXPERIMENTAL ROOM CO., LTD.; LEE SANG B.; Y. J. YONG

CP01 Change in the name or title of a patent holder

Address after: Gyeonggi Do, South Korea

Co-patentee after: S.B.Li

Patentee after: Komi Pharmaceutical International Co.,Ltd.

Co-patentee after: Y.J.Yang

Address before: Gyeonggi Do, South Korea

Co-patentee before: S.B.Li

Patentee before: KOREA MICROBIOLOGICAL LAB Ltd.

Co-patentee before: Y.J.Yang

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070207